Diphencyprone

  • CAT Number: I006492
  • CAS Number: 886-38-4
  • Molecular Formula: C15H10O
  • Molecular Weight: 206.244
  • Purity: ≥95%
Inquiry Now

Diphencyprone (CAT: I006492), also known as diphencypron or diphencyprone, is a synthetic compound that belongs to the class of immunomodulators. It is primarily used in dermatology for the treatment of skin conditions such as alopecia areata and warts. Diphencyprone works by stimulating the immune system and promoting an inflammatory response in the treated area. This immune response helps to target and destroy abnormal or diseased cells, such as those causing hair loss in alopecia areata or the human papillomavirus (HPV) in warts. Diphencyprone is typically applied topically as a solution or cream and requires careful application and monitoring by a healthcare professional due to its immunomodulatory effects.


Catalog Number I006492
CAS Number 886-38-4
Synonyms

Diphencyprone; DPCP and Diphenylcyclopropenone,;2,3-Diphenylcycloprop-2-en-1-one

Molecular Formula C15H10O
Purity ≥95%
Solubility Soluble in DMSO, not in water
Storage 0 - 4°C for short term or -20 °C for long term
Overview of Clinical Research

<span style=”font-family:arial,helvetica,sans-serif;”><span style=”color:#000000;”><span style=”font-size:12px;”>Diphencyprone acts as an immunomodulator. It has been granted its orphan drug status in m<span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>alignant melanoma.</span></span></span></span>

IUPAC Name 2,3-diphenylcycloprop-2-en-1-one
InChI InChI=1S/C15H10O/c16-15-13(11-7-3-1-4-8-11)14(15)12-9-5-2-6-10-12/h1-10H
InChIKey HCIBTBXNLVOFER-UHFFFAOYSA-N
SMILES C1=CC=C(C=C1)C2=C(C2=O)C3=CC=CC=C3
Reference

<br />
1:In vitro human T cell responses to diphencyprone. Friedmann PS, Haddadeen C, Lai C, Healy E.Contact Dermatitis. 2017 Apr;76(4):251-253. doi: 10.1111/cod.12697. No abstract available. PMID: 28317194<br />
2:Topical diphencyprone for Kaposi sarcoma. Abdelmaksoud A.Dermatol Ther. 2017 Mar;30(2). doi: 10.1111/dth.12462. Epub 2017 Jan 30. No abstract available. PMID: 28133860<br />
3:Topical immunotherapy with diphencyprone (DPCP) for in-transit and unresectable cutaneous melanoma lesions: an inaugural Canadian series. Yeung C, Petrella TM, Wright FC, Abadir W, Look Hong NJ.Expert Rev Clin Immunol. 2017 Apr;13(4):383-388. doi: 10.1080/1744666X.2017.1286984. Epub 2017 Feb 6. PMID: 28121191<br />
4:Topical Diphencyprone Immunotherapy for Painful Nodular Acral Recurrence of Kaposi Sarcoma. Pagliarello C, Stanganelli I, Fabrizi G, Feliciani C, Di Nuzzo S.JAMA Dermatol. 2016 Nov 30. doi: 10.1001/jamadermatol.2016.4301. [Epub ahead of print] No abstract available. PMID: 27902811<br />
5:Molecular Profiling of Immune Activation Associated with Regression of Melanoma Metastases Induced by Diphencyprone. Gulati N, Garcet S, Fuentes-Duculan J, Gilleaudeau P, Sullivan-Whalen M, Li X, Su&aacute;rez-Fari&ntilde;as M, Coit DG, Krueger JG.J Invest Dermatol. 2016 Oct;136(10):2101-3. doi: 10.1016/j.jid.2016.06.611. Epub 2016 Jul 1. No abstract available. PMID: 27377699<br />
6:Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment. Gulati N, Carvajal RD, Postow MA, Wolchok JD, Krueger JG.Exp Dermatol. 2016 Jul;25(7):553-4. doi: 10.1111/exd.13030. No abstract available. PMID: 27061281<br />
7:Retrospective review of diphencyprone in the treatment of alopecia areata. Lamb RC, Young D, Holmes S.Clin Exp Dermatol. 2016 Jun;41(4):352-8. doi: 10.1111/ced.12776. Epub 2015 Dec 1. PMID: 26620737<br />
8:Topical diphencyprone for the treatment of locoregional intralymphatic melanoma metastases of the skin; the 5-year Norwich experience. Moncrieff M, Fadhil M, Garioch J.Br J Dermatol. 2016 May;174(5):1141-2. doi: 10.1111/bjd.14314. Epub 2016 Feb 11. No abstract available. PMID: 26598951<br />
9:Diphencyprone Treatment of Alopecia Areata: Postulated Mechanism of Action and Prospects for Therapeutic Synergy with RNA Interference. Bulock KG, Cardia JP, Pavco PA, Levis WR.J Investig Dermatol Symp Proc. 2015 Nov;17(2):16-8. doi: 10.1038/jidsymp.2015.33. PMID: 26551938 Free Article<br />
10:Congenital malignant melanoma and cutaneous metastases treated with diphencyprone. Fawcett JM, Newell EL, Kennedy CT.Clin Exp Dermatol. 2016 Mar;41(2):212-3. doi: 10.1111/ced.12683. Epub 2015 Jun 6. No abstract available. PMID: 26053880

Request a Quote